China: New Covid-19 Vaccine Induces Rapid Immune Response



China: New Covid-19 Vaccine Induces Rapid Immune Response

The new drug is considered the first candidate for the COVID-19 vaccine today.

The Chinese drug manufacturer CanSino Biologics, from the city of Wuhan, developed a vaccine against Covid-19 that has been found to be safe and induces a rapid immune response.

The Lancet released the data from the phase one trial, and considers it the first candidate for the COVID-19 vaccine today.

The findings were released Friday, days after an American biotechnology company announced that it had also developed a vaccine that has proven safe and capable of stimulating an immune response in the human body against the virus.

The drug, developed by Modern biotech, has been challenged, however, after the company failed to share data from its phase one trials.

The drug is known as Covid-19 vaccine vectored by recombinant adenovirus type 5 (AD5), and was tested in 108 healthy adults living in Wuhan who are between 18 and 60 years old.

The researchers tested the volunteers’ blood at regular intervals after they were vaccinated.

They sought to prove that the vaccine stimulated the immune system to produce neutralizing antibodies, which can fight infection and may provide a level of immunity.

They also sought to stimulate the cells of the body, which relies on a group of T cells, rather than antibodies, to fight the virus.


We See The World From All Sides and Want YOU To Be Fully Informed
In fact, intentional disinformation is a disgraceful scourge in media today. So to assuage any possible errant incorrect information posted herein, we strongly encourage you to seek corroboration from other non-VT sources before forming an educated opinion.

About VT - Policies & Disclosures - Comment Policy
Due to the nature of uncensored content posted by VT's fully independent international writers, VT cannot guarantee absolute validity. All content is owned by the author exclusively. Expressed opinions are NOT necessarily the views of VT, other authors, affiliates, advertisers, sponsors, partners, or technicians. Some content may be satirical in nature. All images are the full responsibility of the article author and NOT VT.